BioCryst European marketing application for IV flu therapy accepted for review

• The European Medicines Agency (EMA) accepts for review BioCryst Pharmaceuticals' (NASDAQ:BCRX -7%) Marketing Authorization Application (MAA) seeking approval of peramivir for the treatment of symptoms of influenza in adult patients at least 18 years old. The standard review period is 210 days.
• Peramivir is an intravenous neuraminidase inhibitor. It was approved in the U.S. in December 2014 and is marketed under the brand name Rapivab.